Chronic Plaque Psoriasis Completed Phase 3 Trials for Alefacept (DB00092)

IndicationStatusPhase
DBCOND0033442 (Chronic Plaque Psoriasis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00233662Safety and Tolerability of Repeat Courses of IM AlefaceptTreatment
NCT00673556A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or InappropriateTreatment
NCT00674063A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque PsoriasisTreatment